PTGIR

Prostacyclin receptor · P43119 · PTGIR on Sugi Atlas →

46,302 patent compounds predicted against PTGIR, 26,477 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Treprostinil (SCHEMBL5090)	1.00	12/20
Ornoprostil (SCHEMBL122454)	0.55	10/20
Alprostadil (SCHEMBL33317)	1.00	9/20
Misoprostol (SCHEMBL7787)	0.61	9/20
Misoprostol (SCHEMBL7788)	0.61	9/20
Dinoprostone (SCHEMBL25533)	1.00	6/20
Epoprostenol (SCHEMBL8041)	0.56	6/20
Epoprostenol (SCHEMBL8042)	0.56	6/20
Epoprostenol (SCHEMBL41345)	0.55	6/20
Epoprostenol (SCHEMBL45310)	0.55	6/20
Ciprostene (SCHEMBL34269)	0.52	6/20
Butaprost (SCHEMBL94764)	1.00	5/20
SCHEMBL138467	0.81	5/20
Beraprost (SCHEMBL34593)	0.85	4/20
Epoprostenol (SCHEMBL41344)	0.46	4/20
Epoprostenol (SCHEMBL128619)	0.46	4/20
Temefos (SCHEMBL44105)	0.38	4/20
Domitroban (SCHEMBL98345)	0.86	3/20
Domitroban (SCHEMBL98346)	0.86	3/20
Domitroban (SCHEMBL124474)	0.85	3/20

Clinical trials — most relevant to PTGIR by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease (COPD)	PHASE4	UNKNOWN
Bosentan in Treatment of Pulmonary Arterial Hypertension	PHASE4	COMPLETED
Optimization of Treatment in Patients With Severe Peripheral Ischemia (Fontaine Stage IIb)	PHASE4	COMPLETED
ASpirin vs Triflusal for Event Reduction In Atherothrombosis Secondary Prevention (ASTERIAS)	PHASE4	COMPLETED
Thromboxane Function in Women With Endometriosis	PHASE4	RECRUITING
Pharmacogenomics of Antiplatelet Response - I	PHASE4	COMPLETED
Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite	PHASE2/PHASE3	WITHDRAWN
A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)	PHASE3	COMPLETED
European Celecoxib Trial in Primary Breast Cancer	PHASE3	COMPLETED
Aspirin and Renal Disease Progression in Patients With Type 2 Diabetes	PHASE3	UNKNOWN
Thromboxane Receptor Antagonist to Improve Endothelial Function	PHASE2	COMPLETED
The Arterial Measurement of the Blood Flow Volume After Iloprost Stimulation	PHASE2	UNKNOWN
Prostaglandin Inhibition for Emphysema	PHASE2	COMPLETED
Vascular Effects of Endothelium-Derived Versus Hemoglobin-Transported Nitric Oxide in Healthy Subjects	PHASE1	COMPLETED
Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects	PHASE1	COMPLETED
Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B	nan	COMPLETED
Gap Junction Potentiation of Endothelial Function With Rotigaptide	nan	COMPLETED
Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium	nan	COMPLETED
Pharmacogenomics in Pulmonary Arterial Hypertension	nan	WITHDRAWN
Palmitoylethanolamide in Ulcerative Colitis	nan	NOT_YET_RECRUITING
Lipidomics Screening of Anti-inflammatory Drugs and Drug Candidates in Vitro - Part A	nan	ACTIVE_NOT_RECRUITING
Clinical Research of the Prognostic Influence of NSAIDS's Anti-inflammatory Effect on Senior Patients With Hip Fracture	nan	UNKNOWN
Microvascular Dysfunction and the Development of Whole-body Insulin Resistance	nan	COMPLETED
Relation Between Prostaglandin E2 Metabolite Levels and the Development of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Neonates	nan	RECRUITING
Preoperative Misoprostol in Reducing Blood Loss in Total Abdominal Hysterectomy (TAH)	nan	COMPLETED
Prospective Longitudinal Study of Patients With Idiopathic Pulmonary Arterial Hypertension, Family or Taking Anorectics	nan	COMPLETED
Sleep-disordered Breathing in Eisenmenger Syndrome	nan	COMPLETED
The Role of Cyclooxygenase Activity in the Endothelial Function of Hypertensive and Hypercholesterolemic Patients	nan	COMPLETED
Effect of Pharmacologic Interaction Between ERAs and PDE-5 Inhibitors on Medication Serum Levels and Clinical Disease Status in Patients With PAH	nan	COMPLETED
Core Stability vs. Traditional Physical Therapy: A Comparative Study on Alleviating Low Back Pain in Dysmenorrhea	nan	ENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a PTGIR binder may also engage these)

Protein	Name	Similarity
P79393	—	0.999	P79393 →
P34978	—	0.990	P34978 →
P43252	—	0.990	P43252 →
P43253	—	0.990	P43253 →
P30987	—	0.985	P30987 →
P56486	—	0.983	P56486 →
Q9R261	—	0.981	Q9R261 →
O35932	—	0.978	O35932 →
TBXA2R	Thromboxane A2 receptor	0.977	landscape →
Q62928	—	0.976	Q62928 →
PTGDR	Prostaglandin D2 receptor	0.975	landscape →
Q62053	—	0.974	Q62053 →
P35375	—	0.973	P35375 →
P70263	—	0.973	P70263 →
P70597	—	0.971	P70597 →
PTGER2	Prostaglandin E2 receptor EP2 subtype	0.971	landscape →
A5D7K8	—	0.971	A5D7K8 →
P30557	—	0.968	P30557 →
Q91X56	—	0.967	Q91X56 →
Q9XT82	—	0.967	Q9XT82 →
P46069	—	0.967	P46069 →
PTGER1	Prostaglandin E2 receptor EP1 subtype	0.966	landscape →
S1PR4	Sphingosine 1-phosphate receptor 4	0.966	landscape →
Q95125	—	0.963	Q95125 →
PTGER3	Prostaglandin E2 receptor EP3 subtype	0.963	landscape →
S1PR5	Sphingosine 1-phosphate receptor 5	0.961	landscape →
Q9Z0L1	—	0.961	Q9Z0L1 →
Q95JG1	—	0.960	Q95JG1 →
Q9JKM5	—	0.958	Q9JKM5 →
P34980	—	0.958	P34980 →